One third of patients with metastatic renal cell carcinoma (RCC) suffer from bone metastases.
Skeletal involvement in RCC is associated with the occurrence of skeletal-related events, and may negatively impact on the outcome of patients treated with systemic therapies. In patients with RCC and bone metastases, therapies that inhibit osteoclasts, as bisphosphonates and denosumab, are used as adjunct to systemic targeted therapies to prevent skeletal-related events. Data suggest that they may also improve the outcome of systemic targeted therapies. Herein we review the preclinical and clinical data on their use, as well as remaining open questions.
Written by:
Keizman D, Ish-Shalom M, Maimon N, Gottfried M. Are you the author?
Genitourinary Oncology Service, Institute of Oncology, Meir Medical Center, Sackler School of Medicine, Tel Aviv University, Tchernichovsky 59, 44281, Kfar-Saba, Israel.
Reference: World J Urol. 2013 Mar 31. Epub ahead of print.
doi: 10.1007/s00345-013-1059-6
PubMed Abstract
PMID: 23543006
UroToday.com Renal Cancer Section
